AMRX has been the subject of several other research reports. SunTrust Banks reissued a buy rating and issued a $5.00 price objective on shares of Amneal Pharmaceuticals in a report on Tuesday, August 6th. JPMorgan Chase & Co. lowered Amneal Pharmaceuticals from a neutral rating to an underweight rating in a report on Tuesday. Leerink Swann lowered Amneal Pharmaceuticals from an outperform rating to a market perform rating in a report on Thursday, November 7th. Zacks Investment Research lowered Amneal Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, October 23rd. Finally, Raymond James decreased their price objective on Amneal Pharmaceuticals from $5.00 to $4.00 and set an outperform rating for the company in a report on Thursday, November 7th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. Amneal Pharmaceuticals presently has a consensus rating of Hold and an average target price of $8.50.
AMRX traded down $0.04 during trading hours on Wednesday, hitting $2.71. The stock had a trading volume of 1,856,648 shares, compared to its average volume of 1,463,906. The company’s fifty day simple moving average is $3.05 and its 200 day simple moving average is $5.19. Amneal Pharmaceuticals has a 1 year low of $2.27 and a 1 year high of $19.32. The stock has a market cap of $792.59 million, a PE ratio of 2.85, a price-to-earnings-growth ratio of 2.26 and a beta of 1.48. The company has a quick ratio of 1.50, a current ratio of 2.25 and a debt-to-equity ratio of 6.91.
In related news, SVP Pradeep Bhadauria bought 30,000 shares of Amneal Pharmaceuticals stock in a transaction on Friday, August 16th. The stock was acquired at an average price of $2.41 per share, with a total value of $72,300.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ted C. Nark bought 50,000 shares of Amneal Pharmaceuticals stock in a transaction on Wednesday, August 28th. The shares were bought at an average cost of $2.39 per share, with a total value of $119,500.00. The disclosure for this purchase can be found here. 25.92% of the stock is owned by insiders.
Hedge funds have recently bought and sold shares of the business. Point72 Asset Management L.P. bought a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter valued at about $23,772,000. BlackRock Inc. boosted its position in shares of Amneal Pharmaceuticals by 9.4% during the 2nd quarter. BlackRock Inc. now owns 6,394,923 shares of the company’s stock valued at $45,852,000 after acquiring an additional 549,217 shares during the last quarter. Nuveen Asset Management LLC bought a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter valued at about $2,505,000. Assenagon Asset Management S.A. bought a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter valued at about $971,000. Finally, First Trust Advisors LP bought a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter valued at about $842,000. 34.96% of the stock is owned by institutional investors and hedge funds.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Further Reading: What is the formula for calculating total return?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.